pulmonary fibrosis and/or bone marrow failure, Telomere-related, 3

Summary

pulmonary fibrosis and/or bone marrow failure, Telomere-related, 3 (MONDO:0014613) is a disease caused by RTEL1 (GenCC Definitive), with 5 cohort genes.

At a glance

• Causal gene: RTEL1 (GenCC Definitive)
• Cohort genes: 5
• ClinVar variants: 3,395

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	pulmonary fibrosis and/or bone marrow failure, Telomere-related, 3
Mondo ID	MONDO:0014613
OMIM	616373
UMLS	C4225346
MedGen	901644
GARD	0016098
Is cancer (heuristic)	no

Also known as: PFBMFT3 · pulmonary fibrosis and/or bone marrow failure, Telomere-related caused by mutation in RTEL1 · pulmonary fibrosis and/or bone marrow failure, Telomere-related, 3 · pulmonary fibrosis and/or bone marrow failure, Telomere-related, type 3 · RTEL1 pulmonary fibrosis and/or bone marrow failure, Telomere-related

Data availability: 3,395 ClinVar variants · 4 GenCC gene-disease records.

Disease family

Classification path: disease › human disease › disease by body system or component › respiratory system disorder › lower respiratory tract disorder › lung disorder › interstitial lung disease › pulmonary fibrosis › pulmonary fibrosis and/or bone marrow failure, telomere-related › pulmonary fibrosis and/or bone marrow failure, Telomere-related, 3

Related subtypes (8): pulmonary fibrosis and/or bone marrow failure, Telomere-related, 1, pulmonary fibrosis and/or bone marrow failure, Telomere-related, 2, pulmonary fibrosis and/or bone marrow failure, Telomere-related, 4, pulmonary fibrosis and/or bone marrow failure, telomere-related, 6, pulmonary fibrosis and/or bone marrow failure, telomere-related, 5, pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 7, pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 8, pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 9

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

600 retrieved; paginated sample, class counts are floors:

387 likely benign, 148 uncertain significance, 18 pathogenic, 16 benign, 14 conflicting classifications of pathogenicity, 6 likely pathogenic, 6 pathogenic/likely pathogenic, 5 benign/likely benign

ClinVar	Variant (HGVS)	Gene	Classification	Review
1048767	NM_001283009.2(RTEL1):c.9del (p.Lys3_Ile4insTer)	RTEL1	Pathogenic	criteria provided, single submitter
1068424	NM_001283009.2(RTEL1):c.1236_1266+47del	RTEL1	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
1069534	NM_001283009.2(RTEL1):c.1603G>T (p.Glu535Ter)	RTEL1	Pathogenic	criteria provided, single submitter
1069734	NM_001283009.2(RTEL1):c.2098del (p.Arg700fs)	RTEL1	Pathogenic	criteria provided, single submitter
1070371	NM_001283009.2(RTEL1):c.3043C>T (p.Gln1015Ter)	RTEL1	Pathogenic	criteria provided, single submitter
1071073	NM_001283009.2(RTEL1):c.1458del (p.Ser487fs)	RTEL1	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
1071517	NC_000020.10:g.(?62290746)(62290867_?)del	RTEL1	Pathogenic	criteria provided, single submitter
1071518	NC_000020.10:g.(?62298812)(62298916_?)del	RTEL1	Pathogenic	criteria provided, single submitter
1071780	NM_001283009.2(RTEL1):c.2653G>T (p.Glu885Ter)	RTEL1	Pathogenic	criteria provided, single submitter
1071913	NM_001283009.2(RTEL1):c.3766C>T (p.Gln1256Ter)	RTEL1	Pathogenic	criteria provided, single submitter
1072324	NM_001283009.2(RTEL1):c.329_332del (p.Ile110fs)	RTEL1	Pathogenic	criteria provided, single submitter
1072371	NM_001283009.2(RTEL1):c.3074_3096del (p.Gly1025fs)	RTEL1	Pathogenic	criteria provided, single submitter
1073438	NC_000020.10:g.(?62290746)(62312082_?)del	RTEL1	Pathogenic	criteria provided, single submitter
1075174	NM_001283009.2(RTEL1):c.3553del (p.Arg1186fs)	RTEL1	Pathogenic	criteria provided, single submitter
1076662	NM_001283009.2(RTEL1):c.3138del (p.Ser1047fs)	RTEL1	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
1076689	NM_001283009.2(RTEL1):c.2554C>T (p.Gln852Ter)	RTEL1	Pathogenic	criteria provided, multiple submitters, no conflicts
1076873	NM_001283009.2(RTEL1):c.1194del (p.Ile398fs)	RTEL1	Pathogenic	criteria provided, single submitter
1325019	NM_001283009.2(RTEL1):c.2821G>T (p.Glu941Ter)	RTEL1	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
1342130	NM_001283009.2(RTEL1):c.3109+1G>C	RTEL1	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
1358040	NM_001283009.2(RTEL1):c.1890dup (p.Leu631fs)	RTEL1	Pathogenic	criteria provided, single submitter
1361216	NC_000020.10:g.(?62298812)(62303984_?)del	RTEL1	Pathogenic	criteria provided, single submitter
1364279	NM_001283009.2(RTEL1):c.2584_2593del (p.Leu862fs)	RTEL1	Pathogenic	criteria provided, single submitter
1338484	NM_001283009.2(RTEL1):c.190C>T (p.Arg64Ter)	RTEL1-TNFRSF6B	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
1350840	NM_001283009.2(RTEL1):c.46C>T (p.Gln16Ter)	RTEL1-TNFRSF6B	Pathogenic	criteria provided, single submitter
1066098	NC_000020.10:g.(?62292641)(62327221_?)del	RTEL1	Likely pathogenic	criteria provided, single submitter
1066573	NM_001283009.2(RTEL1):c.1191+1G>A	RTEL1	Likely pathogenic	criteria provided, single submitter
1066646	NM_001283009.2(RTEL1):c.3343+1G>C	RTEL1	Likely pathogenic	criteria provided, single submitter
1066945	NM_001283009.2(RTEL1):c.1266+2T>G	RTEL1	Likely pathogenic	criteria provided, single submitter
1067185	NM_001283009.2(RTEL1):c.2265+1G>T	RTEL1	Likely pathogenic	criteria provided, multiple submitters, no conflicts
1068395	NM_001283009.2(RTEL1):c.3787del (p.Gln1263fs)	RTEL1-TNFRSF6B	Likely pathogenic	criteria provided, single submitter

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 12 · Orphanet: 14 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

Gene	Classification	Inheritance	Disease	Records
RTEL1	Definitive	Semidominant	pulmonary fibrosis and/or bone marrow failure, Telomere-related, 3	12

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
RTEL1	Orphanet:1775	Dyskeratosis congenita
RTEL1	Orphanet:2032	Idiopathic pulmonary fibrosis
RTEL1	Orphanet:3322	Hoyeraal-Hreidarsson syndrome
SCN2A	Orphanet:140927	Self-limited neonatal-infantile epilepsy
SCN2A	Orphanet:1934	Early infantile developmental and epileptic encephalopathy
SCN2A	Orphanet:2131	Alternating hemiplegia of childhood
SCN2A	Orphanet:293181	Epilepsy of infancy with migrating focal seizures
SCN2A	Orphanet:306	Self-limited infantile epilepsy
SCN2A	Orphanet:33069	Dravet syndrome
SCN2A	Orphanet:36387	Genetic epilepsy with febrile seizure plus
SCN2A	Orphanet:697160	Infantile epileptic spasms syndrome
CHRNA4	Orphanet:98784	Sleep-related hypermotor epilepsy
EEF1A2	Orphanet:178469	Autosomal dominant non-syndromic intellectual disability
EEF1A2	Orphanet:442835	Non-specific early-onset epileptic encephalopathy

Cohort genes → proteins

5 cohort genes, 4 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	5

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
RTEL1	HGNC:15888	ENSG00000258366	Q9NZ71	Regulator of telomere elongation helicase 1	gencc,clinvar
SCN2A	HGNC:10588	ENSG00000136531	Q99250	Sodium channel protein type 2 subunit alpha	clinvar
CHRNA4	HGNC:1958	ENSG00000101204	P43681	Neuronal acetylcholine receptor subunit alpha-4	clinvar
EEF1A2	HGNC:3192	ENSG00000101210	Q05639	Elongation factor 1-alpha 2	clinvar
RTEL1-TNFRSF6B	HGNC:44095	ENSG00000026036		RTEL1-TNFRSF6B readthrough (NMD candidate)	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
RTEL1	Regulator of telomere elongation helicase 1	A probable ATP-dependent DNA helicase implicated in telomere-length regulation, DNA repair and the maintenance of genomic stability.
SCN2A	Sodium channel protein type 2 subunit alpha	Mediates the voltage-dependent sodium ion permeability of excitable membranes.
CHRNA4	Neuronal acetylcholine receptor subunit alpha-4	Component of neuronal acetylcholine receptors (nAChRs) that function as pentameric, ligand-gated cation channels with high calcium permeability among other activities. nAChRs are excitatory neurotrasnmitter receptors formed by a collection…
EEF1A2	Elongation factor 1-alpha 2	Translation elongation factor that catalyzes the GTP-dependent binding of aminoacyl-tRNA (aa-tRNA) to the A-site of ribosomes during the elongation phase of protein synthesis.

Protein-family classification

Druggable: 1 · Difficult: 0 · Unknown: 4 · Druggable fraction: 0.2

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Ion channel	1	22.3×	0.088
Other/Unknown	4	1.4×	0.269

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
RTEL1	Other/Unknown	no		Helicase-like_DEXD_c2, ATP-dep_Helicase_C, RAD3-like_helicase_DEAD
SCN2A	Ion channel	yes		IQ_motif_EF-hand-BS, Na_channel_asu, Ion_trans_dom
CHRNA4	Other/Unknown	no		Nicotinic_acetylcholine_rcpt, Neurotrans-gated_channel_TM, Neur_channel
EEF1A2	Other/Unknown	no		T_Tr_GTP-bd_dom, EFTu-like_2, Transl_elong_EF1A_euk/arc
RTEL1-TNFRSF6B	Other/Unknown	no

Expression context

Cohort genes with no expression data: 0.

3 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	5
unknown	0

Top tissues across cohort

Tissue	Cohort genes
cerebellar hemisphere	2
right hemisphere of cerebellum	2
sural nerve	1
Brodmann (1909) area 23	1
cerebellar vermis	1
middle temporal gyrus	1
cingulate cortex	1
cortical plate	1
right lobe of liver	1
apex of heart	1
gastrocnemius	1
hindlimb stylopod muscle	1
cerebellum	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
RTEL1	134	ubiquitous	yes	sural nerve, right hemisphere of cerebellum, cerebellar hemisphere
SCN2A	187	broad	marker	middle temporal gyrus, Brodmann (1909) area 23, cerebellar vermis
CHRNA4	138	tissue_specific	yes	right lobe of liver, cortical plate, cingulate cortex
EEF1A2	247	ubiquitous	marker	gastrocnemius, apex of heart, hindlimb stylopod muscle
RTEL1-TNFRSF6B	135		marker	right hemisphere of cerebellum, cerebellar hemisphere, cerebellum

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
SCN2A	2,810
RTEL1	2,324
CHRNA4	1,989
EEF1A2	745
RTEL1-TNFRSF6B	0

Structural data

PDB: 4 · AlphaFold-only: 0 · No structure: 1

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
CHRNA4	P43681	12
SCN2A	Q99250	5
RTEL1	Q9NZ71	3
EEF1A2	Q05639	2

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 35. Enrichment computed across 5 evidence-associated genes (4 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 4 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Highly sodium permeable postsynaptic acetylcholine nicotinic receptors	1	407.9×	0.026	CHRNA4
Highly calcium permeable nicotinic acetylcholine receptors	1	317.2×	0.026	CHRNA4
Highly calcium permeable postsynaptic nicotinic acetylcholine receptors	1	259.6×	0.026	CHRNA4
Presynaptic nicotinic acetylcholine receptors	1	237.9×	0.026	CHRNA4
Acetylcholine binding and downstream events	1	203.9×	0.026	CHRNA4
Postsynaptic nicotinic acetylcholine receptors	1	203.9×	0.026	CHRNA4
Cytosolic iron-sulfur cluster assembly	1	190.3×	0.026	RTEL1
Resolution of D-Loop Structures	1	158.6×	0.026	RTEL1
Extension of Telomeres	1	150.3×	0.026	RTEL1
Telomere Extension By Telomerase	1	114.2×	0.026	RTEL1
Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)	1	98.5×	0.026	RTEL1
Telomere Maintenance	1	92.1×	0.026	RTEL1
Interaction between L1 and Ankyrins	1	92.1×	0.026	SCN2A
Phase 0 - rapid depolarisation	1	86.5×	0.026	SCN2A
Sensory perception of taste	1	84.0×	0.026	SCN2A
Homology Directed Repair	1	77.2×	0.026	RTEL1
HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA)	1	77.2×	0.026	RTEL1
Eukaryotic Translation Elongation	1	69.6×	0.026	EEF1A2
Sensory perception of sweet, bitter, and umami (glutamate) taste	1	69.6×	0.026	SCN2A
DNA Double-Strand Break Repair	1	62.1×	0.028	RTEL1
Chromosome Maintenance	1	52.9×	0.031	RTEL1
HDR through Homologous Recombination (HRR)	1	47.6×	0.033	RTEL1
L1CAM interactions	1	30.1×	0.050	SCN2A
Cardiac conduction	1	27.2×	0.053	SCN2A
Neurotransmitter receptors and postsynaptic signal transmission	1	25.0×	0.054	CHRNA4
DNA Repair	1	24.6×	0.054	RTEL1
Sensory Perception	1	23.8×	0.054	SCN2A
Muscle contraction	1	19.3×	0.062	SCN2A
Transmission across Chemical Synapses	1	19.0×	0.062	CHRNA4
Axon guidance	1	11.3×	0.098	SCN2A

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 4 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
DNA strand displacement	1	4213.0×	0.003	RTEL1
positive regulation of lipid kinase activity	1	4213.0×	0.003	EEF1A2
negative regulation of telomere maintenance in response to DNA damage	1	4213.0×	0.003	RTEL1
positive regulation of telomeric loop disassembly	1	4213.0×	0.003	RTEL1
intrinsic apoptotic signaling pathway in response to osmotic stress	1	2106.5×	0.004	SCN2A
telomeric loop disassembly	1	2106.5×	0.004	RTEL1
mitotic telomere maintenance via semi-conservative replication	1	1404.3×	0.005	RTEL1
negative regulation of t-circle formation	1	1404.3×	0.005	RTEL1
positive regulation of telomere capping	1	842.6×	0.006	RTEL1
regulation of chaperone-mediated autophagy	1	842.6×	0.006	EEF1A2
positive regulation of telomere maintenance via telomere lengthening	1	702.2×	0.006	RTEL1
DNA repair	2	31.9×	0.006	RTEL1, CHRNA4
behavioral response to nicotine	1	468.1×	0.008	CHRNA4
telomere maintenance in response to DNA damage	1	468.1×	0.008	RTEL1
inhibitory postsynaptic potential	1	421.3×	0.008	CHRNA4
translational elongation	1	300.9×	0.010	EEF1A2
regulation of dopamine secretion	1	300.9×	0.010	CHRNA4
nervous system process	1	300.9×	0.010	CHRNA4
negative regulation of DNA recombination	1	280.9×	0.010	RTEL1
regulation of double-strand break repair via homologous recombination	1	247.8×	0.010	RTEL1
synaptic transmission, cholinergic	1	200.6×	0.012	CHRNA4
cardiac muscle cell action potential involved in contraction	1	175.5×	0.013	SCN2A
acetylcholine receptor signaling pathway	1	156.0×	0.014	CHRNA4
neuromuscular synaptic transmission	1	150.5×	0.014	CHRNA4
positive regulation of telomere maintenance	1	127.7×	0.016	RTEL1
membrane depolarization	1	127.7×	0.016	CHRNA4
neuronal action potential	1	120.4×	0.016	SCN2A
B cell activation	1	113.9×	0.016	CHRNA4
presynaptic modulation of chemical synaptic transmission	1	113.9×	0.016	CHRNA4
replication fork processing	1	105.3×	0.016	RTEL1

Therapeutics

Drug target analysis

Approved (phase 4): 2 · Phase ≥3: 2 · Phased (≥1): 2 · Undrugged: 3

Druggability breadth: 3 of 5 evidence-associated genes (60%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
SCN2A	BEPRIDIL
CHRNA4	VARENICLINE

Top cohort targets by molecule count

Symbol	Molecules	Max phase
SCN2A	99	4
CHRNA4	64	4
RTEL1	0	0
EEF1A2	0	0
RTEL1-TNFRSF6B	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
BEPRIDIL	4	SCN2A
DIBUCAINE	4	SCN2A
ARTICAINE	4	SCN2A
BUPIVACAINE	4	SCN2A
IMIPRAMINE	4	SCN2A
DROPERIDOL	4	SCN2A
DICYCLOMINE	4	SCN2A
TETRABENAZINE	4	SCN2A
PHENIRAMINE	4	SCN2A
PRILOCAINE	4	SCN2A
PROPOXYCAINE	4	SCN2A
PROPARACAINE	4	SCN2A
HEXYLCAINE	4	SCN2A
PRAMOXINE	4	SCN2A
BENOXINATE	4	SCN2A
QUINIDINE	4	SCN2A
FELODIPINE	4	SCN2A
PHENYTOIN	4	SCN2A
QUININE	4	SCN2A
NISOLDIPINE	4	SCN2A
NIFEDIPINE	4	SCN2A
PRAZOSIN	4	SCN2A
DILTIAZEM	4	SCN2A
PRENYLAMINE	4	SCN2A
COCAINE	4	SCN2A
TRIFLUOPERAZINE	4	SCN2A
CINNARIZINE	4	SCN2A
THIORIDAZINE	4	CHRNA4, SCN2A
ETIDOCAINE	4	SCN2A
CHLORPHENIRAMINE	4	SCN2A

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
CHRNA4	624	Binding:497, Functional:125, Toxicity:1, ADMET:1
SCN2A	203	Binding:172, Functional:20, ADMET:10, Toxicity:1
EEF1A2	8	Binding:8

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
SCN2A	203
CHRNA4	624

Pharmacogenomics

Cohort genes with a PharmGKB record: 4; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

30 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
BEPRIDIL	4	SCN2A
DIBUCAINE	4	SCN2A
ARTICAINE	4	SCN2A
BUPIVACAINE	4	SCN2A
IMIPRAMINE	4	SCN2A
DROPERIDOL	4	SCN2A
DICYCLOMINE	4	SCN2A
TETRABENAZINE	4	SCN2A
PHENIRAMINE	4	SCN2A
PRILOCAINE	4	SCN2A
PROPOXYCAINE	4	SCN2A
PROPARACAINE	4	SCN2A
HEXYLCAINE	4	SCN2A
PRAMOXINE	4	SCN2A
BENOXINATE	4	SCN2A
QUINIDINE	4	SCN2A
FELODIPINE	4	SCN2A
PHENYTOIN	4	SCN2A
QUININE	4	SCN2A
NISOLDIPINE	4	SCN2A
NIFEDIPINE	4	SCN2A
PRAZOSIN	4	SCN2A
DILTIAZEM	4	SCN2A
PRENYLAMINE	4	SCN2A
COCAINE	4	SCN2A
TRIFLUOPERAZINE	4	SCN2A
CINNARIZINE	4	SCN2A
THIORIDAZINE	4	CHRNA4, SCN2A
ETIDOCAINE	4	SCN2A
CHLORPHENIRAMINE	4	SCN2A

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	2	SCN2A, CHRNA4
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	3	RTEL1, EEF1A2, RTEL1-TNFRSF6B

Undrugged target profiles

3 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
RTEL1	0	—
EEF1A2	8	—
RTEL1-TNFRSF6B	0	—

Clinical trials & evidence

Clinical trials

Clinical trials: 0.